Share Twitter LinkedIn Facebook Email Mitsuo Hori, MD from Ibaraki Prefectural Central Hospital discusses results of randomized trial of ELd treatment and primary endpoint was met with ORR of 88 with ELd in Japanese patients at the 2017 American Society of Hematology. Advertisement
Advancing Acute Lymphoblastic Leukemia Treatment with CAR-T Cells: Insights from Dr. Anjali Advani Acute Lymphoblastic Leukemia 3 Mins Read
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read